<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST<BR>               <BR>                  <BR>                     Infusion Reactions:  Serious infusion reactions occurred with the administration of Erbitux in approximately 3% of patients in clinical trials, with fatal outcome reported in less than 1 in 1000. [See Warnings and Precautions (5.1)<BR>                        , Adverse Reactions (6)<BR>                        .] Immediately interrupt and permanently discontinue Erbitux infusion for serious infusion reactions. [See Dosage and Administration (2.4)<BR>                        , Warnings and Precautions  (5.1)<BR>                        .]<BR>                  <BR>                  <BR>                     Cardiopulmonary Arrest: Cardiopulmonary arrest and/or sudden death occurred in 2% of patients with squamous cell carcinoma of the head and neck treated with Erbitux and radiation therapy in Study 1 and in 3% of patients with squamous cell carcinoma of the head and neck treated with European Union (EU)-approved cetuximab in combination with platinum-based therapy with 5-fluorouracil (5-FU) in Study 2. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after Erbitux administration.  [See  Warnings and Precautions (5.2, 5.6)<BR>                        ,  Clinical Studies (14.1)<BR>                        .]<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST<BR>                           <BR><BR>                           See full prescribing information for complete boxed warning.<BR>                        <BR>                        <BR><BR>                        <BR>                           <BR>                              Serious infusion reactions, some fatal, occurred in approximately 3% of patients.  (5.1)<BR>                              <BR>                           <BR>                           <BR>                              Cardiopulmonary arrest and/or sudden death occurred in 2% of patients with squamous cell carcinoma of the head and neck treated with Erbitux and radiation therapy and in 3% of patients with squamous cell carcinoma of the head and neck treated with cetuximab in combination with platinum-based therapy with 5-fluorouracil (5-FU). Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after Erbitux administration.  (5.2, 5.6)<BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>